In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moderna Inc.

www.modernatx.com

Latest From Moderna Inc.

Leading From The Lab: MIT’s Robert Langer On The Converging Science Of Drugs, Devices And Delivery

Ten years after our first encounter with MIT’s Robert Langer, In Vivo sits down with the polymath professor – arguably the most inventive and prolific life scientist of his generation – to identify key challenges in medicine. 

Business Strategies StartUps and SMEs

Finance Watch: BIO Report Shows Record VC Funding Across Geographies

Private Company Edition: Venture capital for emerging therapeutics companies in the US and in ex-US regions reached all-time highs in 2018. Also, Alphamab raises $60m Series B, three new VC funds launch and FLX changes its name to RAPT.

Financing StartUps and SMEs

Amgen's KRAS Inhibitor AMG 510 Leans Toward Tumor-Dependent, Not Agnostic, Approach

SVP Elliott Levy said the company hasn't ruled out a tumor-agnostic approach for AMG 510, but Phase I data for the first-in-class drug show a bigger effect in lung cancer – a 50% response rate, so far – than in colorectal cancer patients with a KRAS G12C mutation.

ASCO Cancer

Baby Steps To Real-World Evidence Of Efficacy: External Controls Gain Popularity In Rare Disease Trials

The Pink Sheet takes a closer look at recent clinical announcements showing how rare disease therapy sponsors are already increasingly reliant on natural history studies to guide drug development.

Drug Approval Standards Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Moderna Therapeutics LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Moderna Inc.
  • Senior Management
  • Stephane Bancel, CEO
    Lorence Kim, CFO
    Stephen Hoge, MD, Pres.
    Tal Zaks, MD, PhD, CMO
  • Contact Info
  • Moderna Inc.
    Phone: (617) 714-6500
    200 Technology Square
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register